Physician profile
Howard E Kweller
NPI 1952385494
$3,248.78
in general payments reported to CMS, 2019-2025
34 companies · $610 in 2025
The $610 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $557 · 2021: $393 · 2022: $290 · 2023: $369 · 2024: $284 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $556.79 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $394.66 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $268.62 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $247.99 | 2020-2025 | |
| Amarin Pharma, INC. | $204.04 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.13 | 2019-2025 | Xifaxan |
| Abbvie INC. | $158.07 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $150.56 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.30 | 2019-2022 | |
| Astellas Pharma US INC | $97.58 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $97.48 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.93 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $59.30 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $57.94 | 2019-2024 | |
| Abbott Laboratories | $56.23 | 2021-2023 | Freestyle Libre 3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $46.96 | 2023 | Quviviq |
| Mylan Specialty L.P. | $46.21 | 2021 | |
| Exact Sciences Corporation | $45.77 | 2023-2025 | Cologuard Collection Kit |
| Abiomed | $42.78 | 2025 | |
| Corcept Therapeutics | $40.77 | 2025 | Korlym |
| Novo Nordisk INC | $36.96 | 2022-2025 | Wegovy |
| Glaxosmithkline, LLC. | $30.81 | 2020-2021 | |
| Sanofi Pasteur INC. | $29.48 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $28.46 | 2022 | |
| Merck Sharp & Dohme LLC | $27.22 | 2019-2020 | |
| Axsome Therapeutics, INC. | $26.38 | 2025 | Auvelity |
| Philips North America LLC | $24.55 | 2022 | |
| Sumitomo Pharma America, INC. | $22.59 | 2025 | Gemtesa |
| Vanda Pharmaceuticals INC. | $22.26 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $21.58 | 2025 | Qelbree |
| Edwards Lifesciences Corporation | $19.74 | 2022 | |
| Medtronic, INC. | $16.31 | 2022 | |
| Hologic Sales and Service, LLC | $13.77 | 2019 | |
| Clarus Therapeutics INC. | $13.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Kweller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.